{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phenylephrine+Ophthalmic",
    "query": {
      "intervention": "Phenylephrine Ophthalmic"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phenylephrine+Ophthalmic&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T02:32:39.164Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02946125",
      "title": "Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mydriasis"
      ],
      "interventions": [
        {
          "name": "MDD-administered EYN-1601",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Phenylephrine 2.5% Eyedrop",
          "type": "DRUG"
        },
        {
          "name": "Phenylephrine 10% Eyedrop",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "Eyenovia Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-10",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 1,
      "location_summary": "Artesia, California",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02946125"
    },
    {
      "nct_id": "NCT04831047",
      "title": "The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ptosis, Eyelid",
        "Conjunctiva Inflamed",
        "Eye Manifestations"
      ],
      "interventions": [
        {
          "name": "Oxymetazoline hydrochloride 0.1% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2021-06-08",
      "completion_date": "2022-04-01",
      "has_results": true,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04831047"
    },
    {
      "nct_id": "NCT00748059",
      "title": "The Pathophysiology of Orthostatic Hypotension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autonomic Nervous System Diseases",
        "Orthostatic Hypotension",
        "Dopamine Beta-Hydroxylase Deficiency",
        "Orthostatic Intolerance"
      ],
      "interventions": [
        {
          "name": "Standing or upright tilt",
          "type": "PROCEDURE"
        },
        {
          "name": "Microneurography",
          "type": "PROCEDURE"
        },
        {
          "name": "QSweat",
          "type": "PROCEDURE"
        },
        {
          "name": "neck cuff stimulation",
          "type": "DEVICE"
        },
        {
          "name": "phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine",
          "type": "DRUG"
        },
        {
          "name": "clonidine,yohimbine,metoclopramide,alpha-methyldopa",
          "type": "DRUG"
        },
        {
          "name": "BodPod",
          "type": "PROCEDURE"
        },
        {
          "name": "Eye exam",
          "type": "PROCEDURE"
        },
        {
          "name": "Sleep study",
          "type": "PROCEDURE"
        },
        {
          "name": "Pain response testing",
          "type": "PROCEDURE"
        },
        {
          "name": "Metabolic chamber",
          "type": "PROCEDURE"
        },
        {
          "name": "Brain function studies",
          "type": "PROCEDURE"
        },
        {
          "name": "Bicycle Exercise Test",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "1996-12",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2021-05-12",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00748059"
    },
    {
      "nct_id": "NCT01848041",
      "title": "Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blepharoptosis"
      ],
      "interventions": [
        {
          "name": "RVL-1201",
          "type": "DRUG"
        },
        {
          "name": "RVL-1201 Vehicle Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RVL Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2013-05",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2021-11-26",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 1,
      "location_summary": "Morrow, Georgia",
      "locations": [
        {
          "city": "Morrow",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848041"
    },
    {
      "nct_id": "NCT03615508",
      "title": "Exploration of Pupil Dilation in Horner's Patients Taking Flomax",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Horner Syndrome"
      ],
      "interventions": [
        {
          "name": "10% phenylephrine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denver Health and Hospital Authority",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2018-09-21",
      "completion_date": "2019-05-01",
      "has_results": true,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03615508"
    },
    {
      "nct_id": "NCT01054027",
      "title": "Study on Effective Mydriasis in Premature Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinopathy of Prematurity (ROP)"
      ],
      "interventions": [
        {
          "name": "1% phenylephrine and 0.2% cyclopentolate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "2007-03",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2010-01-22",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01054027"
    },
    {
      "nct_id": "NCT02965924",
      "title": "Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Assess Phenylephrine on EVP and IOP"
      ],
      "interventions": [
        {
          "name": "Phenylephrine 2.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-10",
      "completion_date": "2018-10-01",
      "has_results": true,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02965924"
    },
    {
      "nct_id": "NCT03751098",
      "title": "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mydriasis"
      ],
      "interventions": [
        {
          "name": "Tropicamide/Phenylephrine ophthalmic solution (TR/PE)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eyenovia Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 76,
      "start_date": "2018-12-01",
      "completion_date": "2019-01-21",
      "has_results": true,
      "last_update_posted_date": "2022-03-18",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 2,
      "location_summary": "Austin, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03751098"
    },
    {
      "nct_id": "NCT03536949",
      "title": "Study of Safety of RVL-1201 in Treatment of Blepharoptosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Blepharoptosis"
      ],
      "interventions": [
        {
          "name": "RVL-1201",
          "type": "DRUG"
        },
        {
          "name": "Vehicle ophthalmic solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "RVL Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "9 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2018-06-20",
      "completion_date": "2019-03-27",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 35,
      "location_summary": "Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03536949"
    },
    {
      "nct_id": "NCT01275105",
      "title": "A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate 0.025%",
          "type": "DRUG"
        },
        {
          "name": "Oxymetazoline HCl 0.025%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Therapies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2011-01",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-06",
      "last_synced_at": "2026-09-07T02:32:39.164Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275105"
    }
  ]
}